We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+21.97%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.76B
AUM Growth
+$163M
Cap. Flow
-$58.5M
Cap. Flow %
-2.12%
Top 10 Hldgs %
29.44%
Holding
155
New
9
Increased
52
Reduced
20
Closed
11

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$21.9M
2
EHC icon
Encompass Health
EHC
+$17.3M
3
ALLK
Allakos
ALLK
+$16.6M
4
ELAN icon
Elanco Animal Health
ELAN
+$13.2M
5
ENTA icon
Enanta Pharmaceuticals
ENTA
+$9.27M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$26.1M
2
GILD icon
Gilead Sciences
GILD
+$25.9M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$24.1M
4
ACHC icon
Acadia Healthcare
ACHC
+$22.1M
5
NUVA
NuVasive, Inc.
NUVA
+$19.4M

Sector Composition

Rank Sector Weight
1 Healthcare 89.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABBV icon
26
AbbVie
ABBV
$435B
$30.7M 1.11%
325,000
-275,000
-46% -$26.1M
EXAS
27
DELISTED
Exact Sciences
EXAS
$30.4M 1.1%
385,000
+5,000
+1% +$326K
ZBH icon
28
Zimmer Biomet
ZBH
$18.4B
$29.6M 1.07%
231,750
+65,920
+40% +$7.84M
ONCE
29
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$29.3M 1.06%
537,500
-6,500
-1% -$444K
DVA icon
30
DaVita
DVA
$11.7B
$29.3M 1.06%
408,500
– –
WMGI
31
DELISTED
Wright Medical Group Inc
WMGI
$29M 1.05%
1,000,000
– –
TSRO
32
DELISTED
TESARO, Inc.
TSRO
$28.7M 1.04%
735,000
+109,600
+18% +$3.87M
ALDR
33
DELISTED
Alder Biopharmaceuticals
ALDR
$27.2M 0.98%
1,632,500
+67,500
+4% +$1.22M
ALGN icon
34
Align Technology
ALGN
$12.3B
$26.4M 0.96%
67,500
+1,500
+2% +$553K
ACHC icon
35
Acadia Healthcare
ACHC
$2.94B
$24.6M 0.89%
700,000
-553,500
-44% -$22.1M
INCY icon
36
Incyte
INCY
$24.4B
$24.3M 0.88%
352,100
+56,100
+19% +$3.85M
COLL icon
37
Collegium Pharmaceutical
COLL
$956M
$24.3M 0.88%
1,650,100
+100
+0% +$1.77K
TMO icon
38
Thermo Fisher Scientific
TMO
$220B
$23.4M 0.85%
96,000
– –
NVTA
39
DELISTED
Invitae Corporation
NVTA
$23.4M 0.85%
1,400,000
– –
BAX icon
40
Baxter International
BAX
$14.2B
$22.9M 0.83%
297,000
– –
RDUS
41
DELISTED
Radius Health, Inc.
RDUS
$22.6M 0.82%
1,267,500
+142,500
+13% +$3.22M
PBYI icon
42
Puma Biotechnology
PBYI
$454M
$22.4M 0.81%
487,600
+11,800
+2% +$569K
IDXX icon
43
Idexx Laboratories
IDXX
$46.2B
$20.8M 0.75%
83,500
+11,500
+16% +$2.79M
MDCO
44
DELISTED
Medicines Co
MDCO
$20.6M 0.75%
690,000
– –
OBSV
45
DELISTED
ObsEva SA Ordinary Shares
OBSV
$20.2M 0.73%
1,120,000
– –
AXGN icon
46
Axogen
AXGN
$2.5B
$20M 0.73%
543,474
-1,526
-0.3% -$66.6K
LKFT
47
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
$20M 0.72%
177,500
-7,500
-4% -$792K
WST icon
48
West Pharmaceutical
WST
$24.9B
$19.8M 0.72%
160,000
– –
KYNB
49
Kyntra Bio
KYNB
$29.4M
$18.6M 0.67%
12,240
-40
-0.3% -$61.6K
ALLK
50
DELISTED
Allakos
ALLK
$18.2M 0.66%
+405,000
New +$16.6M
1
2
3 4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q3 2018 Portfolio in Review

As of Q3 2018, Rock Springs Capital Management held 155 positions worth $2.76B, up 6.3% from $2.6B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management's Q3 2018 filing shows 9 new, 52 increased, 20 reduced and 11 closed positions. Its largest new stake was Allakos: 405,000 shares worth $18.2M. The largest sale was AbbVie, an estimated $26.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier.

  • Rock Springs Capital Management's largest Q3 2018 buy was Allakos: 405,000 shares worth $18.2M.
  • Rock Springs Capital Management added most to Boston Scientific in Q3 2018, an estimated $21.9M increase.
  • Rock Springs Capital Management's biggest Q3 2018 reduction was AbbVie, cutting an estimated $26.1M.
  • Rock Springs Capital Management fully exited Gilead Sciences in Q3 2018, selling an estimated $25.9M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $2.76B portfolio in Q3 2018.
  • Rock Springs Capital Management opened 9 new positions and closed 11 in Q3 2018.
  • Rock Springs Capital Management's portfolio value rose 6.3% quarter-over-quarter to $2.76B.

Based on Rock Springs Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.